HeartMate 3 LVAD

With Full Maglev Flow Technology

Clinical Evidence

MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.*1 For the first time in LVAD history, 5-year data is available from this prospective randomized LVAD trial.2

HEARTMATE 3™ LVAD, a proven long-term, life-extending therapy for patients with advanced heart failure

Median survival
5 years

survival at
5 years

Life-prolonging therapy

Life-prolonging therapy in a
patient population who
otherwise would 
not be
expected to survive beyond 9

Reduction in adverse events

Superiority of the HeartMate
 driven by a
in hemocompatibility- related
    adverse events2

Survival comparamble to higher-risk transplant patients

Survival comparable to
higher-risk transplant

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

ELEVATE Registry

The ELEVATE Registry evaluated the real-world experience of the HeartMate 3 LVAD in a post-approval setting.5 5-year extended follow-up showed significant increase in 6-minute walk distance.

Significant Increase in 6-Minute Walk Distance5

Three silhouettes of figures walking along a football field representing the 6-minute walk test. Patients with HeartMate 3 LVAD saw over a two-fold increase in distance.

Quality-of-life improved significantly  and was sustained through 5 years 5

As measured by the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire

Quality-of-life improved

Improved  Safety Profile5

10.8% in first 2 years
3.6% in years 2-5

1.1% at 5 years

All major event types were reduced in the 2-5 years follow-up period compared to 0-2 years, especially hemocompatiblity-related adverse events.

Manuals & Resources

Manuals & Resources

Customer Service

Cardiovascular Products

Customer Service

This device is commercially available for use in select international markets.

*HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
**Patients on inotropes who did not receive a transplant or left ventricular assist device.


  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. September 8, 2022. doi:10.1001/jama.2022.16197
  3. Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Circ Heart Fail. 2015;8(5):880-886.
  4. Kilic et al. Factors associated with 5-year survival in older heart transplant recipients. J Thorac Cardiovasc Surg 2012;143:468-74.
  5. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. Presented at: European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.

MAT-2105164 v2.0